Abstract：The aim of this paper was to observe the clinical effect of gentamycin combined with sodium bicarbonate for the prevention of irinotecan-induced diarrhea. A total of 98 patients with stage IV cancers were recruited and divided into a prevention group (52 patients) and a control group (46 patients). All patients received the chemotherapy including irinotecan. The prevention group received gentamycin and sodium bicarbonate before the use of irinotecan for 4 days; the control group did not receive any prevention. The use of gentamycin and sodium bicarbonate resulted in significantly higher stool pH (P < 0.001), while the incidence of diarrhea by irinotecan was reduced (prevention group 13.70% versus control group 34.83%; P < 0.001). Gentamycin combined with sodium bicarbonate appears to be useful in preventing the diarrhea induced by irinotecan and reducing the dosage of loperamide and fluid replacement.
. Preliminary results of gentamycin combined with
sodium bicarbonate for prevention of irinotecan-induced diarrhea[J]. Front. Med., 2009, 3(4): 470-474.
Qi MEI MM, Zhe CAO MM, Hua XIONG MD, Yuan CHEN MD, . Preliminary results of gentamycin combined with
sodium bicarbonate for prevention of irinotecan-induced diarrhea. Front. Med., 2009, 3(4): 470-474.
Boku N. GastrointestinalOncology Study Group of Japan Clinical Oncology Group. Chemotherapyfor metastatic disease: review from JCOG trials. Int J Clin Oncol, 2008, 13(3): 196―200 doi: 10.1007/s10147-008-0784-0
Maeda Y, Ohune T, Nakamura M, Yamasaki M, Kiribayashi Y, Murakami T. Prevention of irinotecan-induced diarrhoea by oral carbonaceousadsorbent (Kremezin) in cancer patients. Oncol Rep, 2004, 12(3): 581―585
Yang X, Hu Z, Chan S Y, Goh B C, Duan W, Chan E, Zhou S. Simultaneous determinationof the lactone and carboxylate forms of irinotecan (CPT-11) and itsactive metabolite SN-38 by high-performance liquid chromatography:application to plasma pharmacokinetic studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 821(2): 221―228 doi: 10.1016/j.jchromb.2005.05.010
Hahn K K, Wolff J J, Kolesar J M. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm, 2006, 63(22): 2211―2217 doi: 10.2146/ajhp060155
Humerickhouse R, Lohrbach K, Li L, Bosron W F, Dolan M E. Characterization of CPT-11hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res, 2000, 60(5): 1189―1192
Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the activemetabolite of irinotecan. Ann Oncol, 1998, 9(8): 845―847 doi: 10.1023/A:1008438109725
Iyer L, Hall D, Das S, Mortell M A, Ramírez J, Kim S, Di Rienzo A, Ratain M J. Phenotype-genotype correlationof in vitro SN-38 (active metabolite of irinotecan) and bilirubinglucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther1999, 65(5): 576―582 doi: 10.1016/S0009-9236(99)70078-0
de Jong F A, de Jonge M J, Verweij J, Mathijssen R H. Role of pharmacogenetics in irinotecan therapy. Cancer Lett, 2006, 234(1): 90―106 doi: 10.1016/j.canlet.2005.04.040
Mathijssen R H, van Alphen R J, Verweij J, Loos W J, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokineticsand metabolism of irinotecan (CPT-11). Clin Cancer Res, 2001, 7(8): 2182―2194
Iyer L, King C D, Whitington P F, Green M D, Roy S K, Tephly T R, Coffman B L, Ratain M J. Genetic predisposition to the metabolism of irinotecan(CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform1A1 in the glucuronidation of its active metabolite (SN-38) in humanliver microsomes. J Clin Invest, 1998, 101(4): 847―854 doi: 10.1172/JCI915
Kehrer D F, Sparreboom A, Verweij J, de Bruijn P, Nierop C A, van de Schraaf J, Ruijgrok E J, de Jonge M J. Modulation of irinotecan-induceddiarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res, 2001, 7(5): 1136―1141
Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y, Bouscarel B. Intestinal alkalization asa possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res, 2002, 62(1): 179―187
Fassberg J, Stella V J. A kinetic and mechanisticstudy of the hydrolysis of camptothecin and some analogues. J Pharm Sci, 1992, 81(7): 676―684 doi: 10.1002/jps.2600810718
de Jong F A, Kehrer D F, Mathijssen R H, Creemers G J, de Bruijn P, van Schaik R H, Planting A S, van der Gaast A, Eskens F A, Janssen J T, Ruit J B, Verweij J, Sparreboom A, de Jonge M J. Prophylaxis of irinotecan-induceddiarrhea with neomycin and potential role for UGT1A1*28 genotype screening:a double-blind, randomized, placebo-controlled study. Oncologist, 2006, 11(8): 944―954 doi: 10.1634/theoncologist.11-8-944
